Ranbaxy's US Gloversville plant to close but little impact expected
This article was originally published in Scrip
Executive Summary
The closure of Ranbaxy Laboratories' US liquid manufacturing facility in Gloversville, New York, which has seen little commercial activity over the recent past, is not expected to have any major financial impact on the firm's operations.